Valeant Pharmaceuticals has signed a definitive agreement to acquire Dow Pharmaceutical Sciences (DPS), Inc. According to a Valeant statement, the transaction will boost Valeant’s dermatology franchise in the U.S. through the acquisition of a specialized dermatology R&D organization, including a newly approved product and a robust pipeline of five dermatology products, three of which are in Phase II clinical development. Valeant will pay Dow $285 million, subject to certain closing...